The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | The safety and efficacy of HBI0101 for the treatment of R/R myeloma
In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses results from a study evaluating the safety and efficacy of HBI0101, a novel academic CAR-T, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lebel summarizes the safety profile of this agent, as well as the response rates, rates of measurable residual disease (MRD) negativity, and progression-free survival (PFS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
